NEWSROOM | Galderma

Galderma launches Alastin® in Japan and key markets across Asia Pacific, expanding its footprint in the region

Landmark global Galderma survey shows 9 out of 10 people are affected by skin quality concerns

Galderma provides progress update regarding RelabotulinumtoxinA regulatory submission in the United States

Prurigo nodularis: The burden of diagnostic delay

Galderma unveils new global survey data exploring the evolving expectations and experiences of patients and healthcare professionals with anti-wrinkle treatments

Beyond breakouts: acknowledging the full burden of acne

Galderma receives U.S. FDA approval for Differin® Epiduo® Acne Gel Prescription-to-OTC switch

Understanding connections across inflammatory skin conditions: the SKIN approach

Galderma reports strong start to the year, delivering first quarter 2026 net sales of 1.473 billion USD, growing 25.5% at constant currency

Galderma shareholders approve all Annual General Meeting proposals

Galderma launches new Alastin Regenerating Skin Nectar with TriHex+™, powered by its next-generation TriHex Technology® regenerative platform

Interim data from two ongoing investigator-initiated trials highlight the role of Sculptra® and Restylane® in addressing aesthetic changes associated with weight loss medications and menopause

Galderma debuts ALASTIN Signature Practices in partnership with leading aesthetic practices to elevate regenerative, peri-procedural skincare